Paxton Mills is one of the newest members of NYLI, of the 2023 cohort. Paxton has been actively involved in the inheritable blood and bleeding disorders community since her diagnosis with having a rare platelet disorder.
Octapharma’s human plasma-derived von Willebrand Factor (VWF)/Factor VIII replacement product Wilate® has been granted expanded approval for prophylaxis by the U.S. Food and Drug Administration (FDA) to include all types of von Willebrand disease (VWD).
Hemophilia Memorial at the National AIDS Memorial Grove in Golden Gate Park opened in September 2017
Researchers in San Francisco, New York, and Oxford describe a new type of hemophilia, arising from a defect in what is now known as factor IX (9). Rosemary Biggs from Oxford, UK, named it Christmas disease, after the first patient, Stephen Christmas.
